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b cell dysfunction is sufficient to cause hyperglycemia; b cell loss is not necessary but, if severe, can be suffi-
cient andmay be accompanied by intrinsic b cell dysfunction. Clinical testing can differentiate b cell capacity
from b cell glucose sensitivity but cannot ascribe either to relative changes in b cell mass versus function.
However, longitudinal and intervention studies indicate that b cell glucose insensitivity (stunning) closely
tracks with hyperglycemia and is, at least in part, reversible. Rescuing stunned b cells is a key therapeutic
target.The endocrine pancreas is a small, diffuse
organ estimated to be made up of one
million islets, each endowed with 1000
b cells, for a total weight of 0.9 g.
Despite its size, like virtually every other
organ, the endocrine pancreas has a con-
siderable functional reserve; even simply
in terms of stored hormone, pancreatic
insulin content has been estimated to
range from 200 to 250 units (10 days
worth of supply for a healthy adult) (Rahier
et al., 2008). Therefore, using its capacity
and flexibility, the islets can accommo-
date a wide range of insulin demand.
Typically, surgical removal of 50% of
the pancreas results in usually minor
deterioration of glucose tolerance in man
and animals. Whereas the attendant
reduction in a cell number contributes
to limit hyperglycemia, just about half
a gram of remnant endocrine tissue can
grant lifelong glucose control. Symmetri-
cally, insulin secretion can cope with
extremes of body size. For example, it
has been calculated that a lean, insulin-
sensitive adult may need as little as 0.5
units of insulin to dispose of an oral load
of 75 g of glucose over 2 hr, whereas an
obese, insulin-resistant, glucose-intol-
erant subject may require 45 units to per-
form the same task, an 100-fold span
(Ferrannini et al., 2007). Equally striking
is the case of bariatric surgery: in morbidly
obese, nondiabetic subjects who had lost
50 kg of weight following the operation,
insulin output dropped by 60%—from a
median of 65 to 25 units per day—in con-
comitance with normalization of insulin
resistance (Camastra et al., 2005). Fur-
thermore, an intravenous glucose bolus
elicits a surge of insulin secretion within
less than 1 min, a time constant of stim-ulus-secretion coupling only second to
that of neuroendocrine systems. Thus,
as a physiological unit, b cells exhibit both
high-capacity—i.e., absolute rates of
insulin release—and high-sensitivity pro-
perties—i.e., rapid and robust response
to glucose increments.
Does b cell mass underlie b cell secre-
tory capacity? Estimates of b cell mass
in humans all rest on morphometric anal-
yses of autopsy specimens. Subject sam-
ple size, information on clinical status,
tissue preservation, dyshomogeneity of
intrapancreatic islet distribution, and kind
of measure (b cell relative volume versus
b cell mass) confound such post mortem
determinations and presumably contrib-
ute to the wide between subject variation
in b cell mass found in these studies.
Nevertheless, the literature is consistent
in indicating that the nondiabetic obese
individual has an expanded islet mass.
According to the two largest and most
recent studies, as compared to lean indi-
viduals with a BMI of 22–23 kg/m2, b cell
mass was increased by 20% in subjects
with an average BMI of 30 kg/m2 (Rahier
et al., 2008) and b cell relative volume
was increased by 50% in subjects with
a BMI of 38 kg/m2 (Butler et al., 2003),
both estimates being much lower than
in obese rodents. Thus, in nondiabetic
subjects, estimates of b cell mass do
parallel measurements of insulin secre-
tory capacity qualitatively but fall short
of a strictly proportional relationship.
In particular, it is implausible that, in
calorie-restricted subjects, b cells should
be vanishing as insulin output decreases
to the extent seen with bariatric surgery.
Therefore, from a quantitative standpoint,
adaptation of b cell function (i.e., activa-Cell Metabolistion of key enzymes and transcription
factors, upregulation of genes) appears
to account for the larger part of the
changes in insulin secretion seen in asso-
ciation with changes in body size in nondi-
abetic individuals.
Does b cell mass determine, or even
track, the dynamic properties of the
b cell? This is an even more intractable
question. The cellular and molecular
biology of the b cell is extraordinarily
complex: the b cell integrates multiple
inputs—both stimulatory and inhibitory—
to mount a secretory response. However,
at a whole-body level, the functional
behavior of b cells can be reduced to
a few basic rules. Although insulin exerts
actions on carbohydrate, lipid, protein,
and electrolyte metabolism, the dominant
physiological feedback is on glucose:
what is primarily needed is to avoid hypo-
glycemia (life threatening) as well as
hyperglycemia (in the long term, toxic
to tissues) by confining plasma glucose
excursions within a very narrow range
(only 3 mmol/l in normal adults). There-
fore, insulin release must not only be suffi-
cient in quantity to elicit effects in target
tissues (i.e., restraining glucose output
by the liver and promoting glucose uptake
into muscle and fat), but also appropriate
in timing: delayed secretion of normal
amounts of hormone is associated with
hyperglycemia (compare the blue and
red insulin responses to oral glucose
[OGTT] in Figure 1B: the area under the
respective curves is similar, yet subjects
with the red insulin response have dia-
betic glucose levels [Figure 1A]). In fact,
to attain tighter homeostasis, insulin
release must also be able to anticipate
glucose rises and prevent persistentm 11, May 5, 2010 ª2010 Elsevier Inc. 349
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Figure 1. The Concept of b Cell Glucose Sensitivity
(A–D) Plasma glucose (A) and insulin concentrations (B) in response to an oral glucose load in lean nondi-
abetic subjects (blue lines), obese nondiabetic subjects (green lines) matched to the lean by glucose toler-
ance (i.e., fasting and 2 hr plasma glucose levels), and patients with type 2 diabetes (red lines) matched to
the obese subjects by BMI. The data in (A) and (B) are plotted against each other in panel (C), with the cor-
responding linear fits. In (D), insulin concentrations were converted into insulin secretion rates using
C-peptide deconvolution. The average slope of the lines is b cell glucose sensitivity, measured in pmol
per min per square meter of body surface area per mmol/l of plasma glucose (pmol$min1.m2.mM1).
Symbols plot means ± SEM (unpublished data).
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terms, insulin secretion should be (1)
coupled to glucose levels through a steep
dose-response relationship, (2) rate sen-
sitive by reading the rate of change in
glucose levels, and (3) capable of potenti-
ation by some form of glucose memory.
These dynamic properties must be
preserved across a range of absolute
insulin secretion rates as demanded by
obesity and insulin resistance (compare
the blue and green lines in Figure 1B: the
area under the green curve is approxi-
mately three times that under the blue
curve, yet glucose levels are almost
superimposable between the two groups
[Figure 1A]). Remarkably, these basic
physiological requirements are all con-
firmed by studies of isolated human
islets, which have demonstrated dose
dependency, rate sensitivity, and potenti-
ation of glucose-induced insulin release
(Henquin et al., 2006).
Nevertheless, despite the overall
coherence of the in vitro with the in vivo
physiology of the b cell, it is, at present,
virtually impossible to tell whether any
difference in b cell sensitivity (or rate350 Cell Metabolism 11, May 5, 2010 ª2010sensitivity or potentiation) that is
observed in vivo is due to differences in
b cell mass or function. To illustrate this
point, consider Figure 1C, in which the
plasma insulin concentrations at the var-
ious times during the OGTT (Figure 1B)
are plotted against the corresponding
plasma glucose levels (Figure 1A) sepa-
rately for the three groups of subjects.
In the obese versus the lean subjects
with normal glucose tolerance, insulin
levels are higher at each given plasma
glucose level, but the slope of the fitting
line is similar. Thus, the set point of insulin
release is shifted upwards (= enhanced
capacity), but the ability to acutely
increase insulin release with increasing
glycemia (= glucose sensitivity) is approx-
imately the same. This result, which could
be explained by an upregulation of b cell
capacity, is also theoretically compatible
with the obese having more b cells, each
of standard glucose capacity and sensi-
tivity. In contrast, type 2 diabetic subjects
require much higher glucose levels to
achieve similar insulin concentrations
to lean controls (for example, 12 versus
7 mmol/l to reach 300 pmol/l), i.e., theyElsevier Inc.show impaired glucose sensitivity. Fur-
thermore, even at high glucose levels,
the majority of diabetic subjects do not
reach the maximal insulin concentrations
achieved by nondiabetic subjects; con-
versely, raising plasma glucose of the
nondiabetic into the diabetic range would
result in much higher insulin levels than
seen in the diabetic. Incidentally, it could
be argued that the pattern of results in
Figure 1 is peculiar to the stimulus used,
namely an oral glucose load, or that it is
confounded by measures of peripheral
insulin concentrations rather than true
insulin secretion rates. However, Polon-
sky’s group (Cavaghan et al., 2000)
reported a similar shift in in vivo b cell
glucose sensitivity in diabetic as com-
pared to nondiabetic subjects using
graded intravenous glucose infusions,
which rules out confounding by gas-
trointestinal factors. In fact, b cell glu-
cose sensitivity has been shown to be
depressed in proportion to the degree of
hyperglycemia even within the normal
range of glucose tolerance (Ferrannini
et al., 2005). Furthermore, when insulin
secretion rates are reconstructed from
C-peptide concentrations (by deconvolu-
tion analysis [Cavaghan et al., 2000;
Ferrannini et al., 2005]), the pattern is the
same: the slope of insulin secretion-
plasma glucose dose-response relation-
ship is flatter in diabetic than nondiabetic
subjects (Figure 1D). Here again, a normal
number of b cells each with impaired
sensitivity would explain the data, but so
would a substantially lower number of
normally glucose-sensitive b cells.
In summary, even with use of such
simple measurements as plasma glucose
and insulin levels on a standard OGTT
(Figure 1), one can retrieve and quantify
meaningful differences in b cell capacity
(e.g., obese versus lean) and glucose
sensitivity (e.g., diabetic versus nondia-
betic); neither set of differences, however,
can be imputed to differences in b cell
mass or function alone with certainty.
This conclusion appears to clash with
the notion that b cell mass is low in dia-
betes, which has been revamped by
recent studies reporting an average
40%–60% reduction of b cell relative
volume in patients with type 2 diabetes
(Butler et al., 2003). In fact, in the latter
series, a halving of b cell relative volume
was found also in subjects with impaired
fasting glucose, a milder form of glucose
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Figure 2. Schematic Plot of b Cell Function versus b Cell Mass in
Normal, Nondiabetic Obese Subjects and Diabetic Subjects
The stippled areas represent the range of changes in b cell function observed
with weight loss and improved glycemic control (reduced capacity and
unchanged glucose sensitivity in the obese nondiabetic, increased capacity
and increased glucose sensitivity in the diabetic); the corresponding changes
in b cell mass are hypothetical. The dotted blue lines stand for the associated
changes in glucose tolerance (marginally impaired in obesity, profoundly
decreased in diabetes, reversible) and insulin resistance (present in both
obesity and diabetes, reversible).
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study in a small group of
patients undergoing pancrea-
tectomy (Meier et al., 2009)
reported a close correlation
between b cell relative area
and presurgery plasma glu-
cose response to oral glu-
cose, a surprising finding in
view of the known vari-
ability—spontaneous as well
as treatment induced—of the
OGTT. This kind of observa-
tion resonates with morpho-
logical and histochemical evi-
dence documenting disarray
of islet structure and amyloid
infiltration in human diabetic
islets. Moreover, the vast
majority of gene variants that
genome-wide scans have
associated with type 2 dia-
betes are related to some
aspect of b cell function or
survival. Clinical testing, on
the other hand, has contrib-
uted to the confusion, marredas it is by a host of methodological
and interpretive difficulties. Though years
of clinical research have yielded an
accepted gold standard for the in vivo
measurement of insulin sensitivity,
namely, the euglycemic hyperinsulinemic
clamp technique, b cell function is still
assessed with methods employing dif-
ferent stimuli (glucose, arginine, glu-
cagon, mixed meals), route (oral, intrave-
nous), and format of administration
(bolus injection, graded infusion, hyper-
glycemic plateau). The respective metrics
have spanned from crude empirical
indices (HOMA-B, insulinogenic index on
the OGTT, acute insulin response on the
IVGTT) to more ambitious constructs
(the disposition index) and formal mathe-
matical modeling. As a consequence,
the etiologic paradigm of type 2 diabetes
may have been shifting toward a ‘‘mass’’
problem, as the primary cause of b cell
dysfunction, one that is present early in
the natural history of diabetes, is possibly
detectable in vivo (pending the refinement
of novel imaging techniques) and thera-
peutically ‘‘drug-able’’ (using trophic fac-
tors or stem cells).
However, (1) autopsy specimens
frequently are from sick patients of
advanced age, whose glucose intoler-
ance is uncertain in degree (subjectswith impaired fasting glycemia might be
diabetic on the OGTT) as well as duration;
(2) in more recent series, b cell mass was
quasi-normal at the time of clinical diag-
nosis of diabetes (Rahier et al., 2008)
and was normal in lean patients with
recent onset diabetes (Hanley et al.,
2010); (3) islet amyloidosis could be the
consequence, rather than the cause, of
hyperglycemia; (4) when islets obtained
from donors with type 2 diabetes are
studied under ‘‘healthy’’ culture condi-
tions, they show defective responses to
glucose (Marchetti et al., 2004); (5) b cell
glucose insensitivity antecedes and inde-
pendently predicts the emergence of dys-
glycemia in young subjects with normal
glucose tolerance (Walker et al., 2005),
that is, at a time when b cell mass would
be mostly preserved; (6) intensified insulin
therapy or, indeed, any treatment result-
ing in marked amelioration of glycemic
control is associated with partial reversal
of b cell insensitivity and enhanced b cell
capacity; and (7) bariatric surgery is fol-
lowed by long-lasting resolution of dia-
betes in a high proportion of type 2
patients, in some cases with full recovery
of b cell glucose sensitivity. Because, in
human adults, b cell regeneration appears
to occur at a very low rate, changes in
b cell mass can hardly explain recoveryCell Metabolism 11, May 5of function; it follows that
b cell mass deficit alone is
unlikely to be the primary
cause of most cases of dia-
betes, whereas b cell dys-
function theoretically could
be the sole mover.
All in all, the available evi-
dence is compatible with the
following construct. b cell
dysfunction is sufficient to
cause hyperglycemia; re-
duced b cell mass is not
necessary but, if severe, can
be sufficient, i.e., it may or
may not be associated with
intrinsic b cell dysfunction.
In a timescale of months or
years, insulin resistance mod-
ulates b cell capacity (or set
point), at least in part, by
driving b cell mass expansion;
the impact of obesity is par-
tially mediated by insulin
resistance. (A further level of
complexity would be added
if insulin resistance at the levelof the b cell was negatively affecting its
function or mass, a possibility that is still
being explored). As a result, in obese
subjects with normal glucose tolerance,
b cell mass is increased, b cell capacity
is upregulated, but glucose sensitivity is
normal; weight loss restores capacity,
possibly with some effect on b cell
mass. In glucose-intolerant/diabetic sub-
jects, mass may be reduced—particularly
with long-standing hyperglycemia—and
b cells are markedly dysfunctional in
capacity as well as glucose sensitivity,
but euglycemia and weight loss improve
both modes of b cell function, presumably
in the absence of major changes in b cell
mass (Figure 2).
If pathogenesis can be reduced to a few
interacting mechanisms, clinical diabetes
is nothing like its pathogenesis, com-
prised as it is of multiple subphenotypes,
dyshomogeneous for other factors in
addition to pathophysiology. Conceiv-
ably, there are people who are born with
a small pancreas, secondary to stunted
growth during early pregnancy (the so-
called small baby syndrome). In them,
a poor endowment of b cells is the context
against which acquired burden in adult life
leads to glucose intolerance. In other
subjects with a normal number of b cells,
an intrinsic (genetic?) defect of b cell, 2010 ª2010 Elsevier Inc. 351
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diabetes. In still another group of patients
born with a normal number of normal
b cells, an environmental injury slowly
erodes b cell mass or paralyzes their
glucose sensing but goes unnoticed
and is lumped together with the other
subgroups under the heading of type 2
diabetes. Finally, there are the adult
patients whose b cell mass (and, perhaps,
function) is compromised by a slow auto-
immune attack (latent autoimmune dia-
betes of adulthood), who may likewise
be misclassified as type 2 patients. What
is of paramount importance is that, in
each member of this (incomplete) list of
subphenotypes, age and chronic hyper-
glycemia each accumulate demise of
both b cell mass and function. Age con-
veys low-penetrance genetic influences,
comorbidities, weight gain, sedentari-
ness, vascular dysfunction, and drug
toxicity. Chronic hyperglycemia is a well-
known perpetrator of widespread tissue
damage that hits the islet both by com-
promising vascular and neural supply
and by directly blunting b cell response
to glucose; it does so in vitro—where
exposure to high glucose for a few days
is sufficient to alter the subsequent secre-
tory response to glucose stimulation—
and it does so in vivo under experimental
circumstances. Glucose toxicity is an
undisputed fact, incompletely understood
but solidly established. In support of this
notion, in Rahier’s autopsy series (Rahier
et al., 2008), b cell mass showed a signifi-
cant negative association with diabetes
duration despite the great variability of
the measures. An important role for the
duration of hyperglycemic exposure is
also borne out by in vivo data in diabetic
patients, in whom b cell glucose sensi-
tivity is reciprocally related to disease
duration even after adjusting for the
severity of the hyperglycemia (data not
shown).
From these grounds emerges the
concept that a fairly common pathophys-
iological element across hyperglycemic352 Cell Metabolism 11, May 5, 2010 ª2010syndromes is, what can be called, the
stunned b cell (by analogy with the postin-
farctionmyocardium): a cell that is tempo-
rarily unable to appropriately sense its
primary stimulus but may recover compe-
tence, at least in part. Indeed, there can
be no harm in just assuming that every
dysglycemic person has some stunned
b cells that can be retrieved into function
and that every person at risk of dia-
betes—for reasons of genes, birth, or
environment—has b cells that can be
spared from stunning. The correlation
between b cell glucose sensitivity and
glycemia is so tight (Figure 1) that any
improvement of the former begets a
decrement in the latter and vice versa.
From the clinical standpoint, restoring
b cell mass is a distant therapeutic aim;
under the circumstances, the key target
in the treatment and prevention of the
epidemic of hyperglycemia is hypergly-
cemia itself. There are better means today
than ever in the past to rescue stunned
b cells. We have good evidence that
revving up insulin sensitivity by insulin-
sensitizing drugs will relieve pressure on
an endangered b cell population, thereby
inducing more durable glycemic control.
Following up on the observation that
GLP-1 can restore euglycemia in patients
with type 2 diabetes by markedly potenti-
ating b cell function (through cAMP-
dependent pathways), incretin-based
treatments (DPP-IV inhibitors and GLP-
1-receptor agonists) are in clinical
apprenticeship. Activating b cell glucoki-
nase—the first committed step for
glucose-induced insulin release—may
be feasible in vivo if the attendant risk of
hypoglycemia can be smoothed out.
Several other potential therapeutic tar-
gets within the b cell are being probed
pharmacologically. Glycosuric agents,
which allay glucose toxicity in an insulin-
independent fashion, may become usable
drugs. Early, intensified insulin therapy—
even just a short course of a few
weeks—can grant newly diagnosed dia-
betic patients a lasting remission or, atElsevier Inc.least, a prolonged honeymoon phase.
Early combination treatment is being
explored, and oral insulin formulations
may eventually exhibit an absorption
pattern that is reproducible enough to be
safely exploited in patients. For the time
being, there appears to be sufficient ratio-
nale to propose that bringing any degree
of hyperglycemia under as tight control
as allowed by safety and as early as
possible can awaken stunned b cells,
whatever their past history and genetic
program may be in the individual patient.REFERENCES
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